{"id":535586,"date":"2021-09-08T08:33:42","date_gmt":"2021-09-08T12:33:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/"},"modified":"2021-09-08T08:33:42","modified_gmt":"2021-09-08T12:33:42","slug":"daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/","title":{"rendered":"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Oak Ridge, TN, Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Um23jwp_2Pry376_17IRYbmlFPfagfaWyxprp9_9R0clOg1QEeN2o8LWLZEbv-YeTXtO0KdFa8DUPQ_EjTmIlA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Daxor<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hLKFpXOYRZdU2KWu5ctaIbrNU-wGRZKriMTaLioONh-jzJiNdFGnO7eXI81yoWHhzOhYrX4_5vysfijhKj_yk72g2gDZVfMCQ0vWhy0abt4=\" rel=\"nofollow noopener\" target=\"_blank\"><u> Corporation<\/u><\/a> (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 \u2013 which brings together the world\u2019s leading experts in heart failure from September 10-13, 2021. This year\u2019s ASM provides a hybrid format; in-person at the Gaylord Rockies in Denver, Colorado or live virtually across the globe.<\/p>\n<p align=\"justify\">\u201cThis is the strongest HFSA program in Daxor\u2019s history. We are excited to feature new trials as well as outcome data with clinical partners from leading institutions,\u201d stated Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation. New data highlighting the applicability of blood volume analysis (BVA) titled, <em>\u201cValue of Blood Volume Analysis in Patients with Left Ventricular Assist Devices\u201d <\/em>(Poster #059), <em>\u201cVolume-Guided Venous <\/em><em>To<\/em><em> Venous Ultrafiltration in Hospitalized Heart Failure Patients\u201d <\/em>(Poster #089), and <em>\u201cThe Phenotype of Polycythemia and Hypervolemia in Hospitalized Heart Failure Patients\u201d <\/em>(Poster #117) will be featured on-line and in the e-Poster Hall.<\/p>\n<p align=\"justify\">\u201cThe HFSA\u2019s Annual Scientific Meeting is the premier event that gathers the best scientific minds focused on the latest heart failure science, research and patient management,\u201d said Michael Feldschuh, CEO of Daxor Corporation. \u201cWe are looking forward to sharing with leaders two landmark research studies featured in Clinical Trial Row underway including a National Institute of Health (NIH) funded randomized multicenter control trial with the U.S. Department of Veterans Affairs applying BVA-100 guided care to improve hospitalized heart failure outcomes, a patient population of over 1 million domestically. Equally important is an outpatient prospective randomized trial for heart failure management featuring next generation technology developed through contracts awarded by the U.S. Department of Defense and funded by the Center for Advancing Point of Care Technologies (CAPCaT)\/NIH, also measuring the benefit of the BVA-100 test for improving ambulatory heart failure patient care, a population that numbers more than 6 million in the U.S. alone.\u201d<\/p>\n<p>The company will be exhibiting at Booth 109.<\/p>\n<p>Register for the event here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AG7oTHQewYMpYOWZK8kz8MMehT6zxn6tiFFt9CIaJD8xGVoGtnANzjgQFipujV6ytLJt9z9-8zQg9AH-nLMigHZNyiNPSq-q7tc3o04SYwMSNo8d6xKNrmMfOqqNsvz_r0g-H9Ecr4rp13qf6lJZHDxfr8gofKPEeVWULt4SXjY=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/hfsa.org\/annualscientificmeeting\/registration<\/u><\/a>.<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>Daxor<\/strong><br \/>\n        <strong> Corporation<\/strong>\n      <\/p>\n<p align=\"justify\">Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100<sup>\u00ae<\/sup> (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor&#8217;s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor\u2019s vision is optimal blood volume for all. For more information, please visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hlLpiDN3EmTbaiFg1WwuYwldS8tDwjccL8QwgYJ6VGqnrzp6ufYP1xPkY-NM2cSkRmiIUx_J8mKd4GthWyWIwA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Daxor.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Bret Shapiro<br \/>Sr. Managing Partner, CORE IR<br \/>516-222-2560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TqbgMyWGkarLlZgJIj2k4mXOHv0uFtsNGnzi9APdyx9VPCmAkNVf26D9d3PPqlrYIu-IZQkAZkbzssiQD49CuQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>brets@coreir.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTRhMWY3MTYtNDg2ZC00OWY0LWJmNGItNDQ4YzkzODllMTQ4LTEwOTU5MTc=\/tiny\/Daxor-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 \u2013 which brings together the world\u2019s leading experts in heart failure from September 10-13, 2021. This year\u2019s ASM provides a hybrid format; in-person at the Gaylord Rockies in Denver, Colorado or live virtually across the globe. \u201cThis is the strongest HFSA program in Daxor\u2019s history. We are excited to feature new trials as well as outcome data with clinical partners from leading institutions,\u201d stated Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation. New data highlighting the applicability of blood volume &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535586","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 \u2013 which brings together the world\u2019s leading experts in heart failure from September 10-13, 2021. This year\u2019s ASM provides a hybrid format; in-person at the Gaylord Rockies in Denver, Colorado or live virtually across the globe. \u201cThis is the strongest HFSA program in Daxor\u2019s history. We are excited to feature new trials as well as outcome data with clinical partners from leading institutions,\u201d stated Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation. New data highlighting the applicability of blood volume &hellip; Continue reading &quot;Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021\",\"datePublished\":\"2021-09-08T12:33:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/\"},\"wordCount\":704,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/\",\"name\":\"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=\",\"datePublished\":\"2021-09-08T12:33:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021 - Market Newsdesk","og_description":"Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021 \u2013 which brings together the world\u2019s leading experts in heart failure from September 10-13, 2021. This year\u2019s ASM provides a hybrid format; in-person at the Gaylord Rockies in Denver, Colorado or live virtually across the globe. \u201cThis is the strongest HFSA program in Daxor\u2019s history. We are excited to feature new trials as well as outcome data with clinical partners from leading institutions,\u201d stated Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation. New data highlighting the applicability of blood volume &hellip; Continue reading \"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:33:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021","datePublished":"2021-09-08T12:33:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/"},"wordCount":704,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/","name":"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=","datePublished":"2021-09-08T12:33:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTk5MiM0Mzk0MjYzIzIwODQzNDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-to-present-compelling-new-data-and-clinical-trials-utilizing-the-bva-100-blood-test-at-the-heart-failure-society-of-america-annual-scientific-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100\u00ae Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535586"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535586\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}